---
title: Histopathologic and Clinical Characterization of Brentuximab Vedotin-associated
  Rash
date: '2024-06-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38907612/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240623182349&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Rash is one of the commonly observed adverse events with brentuximab
  vedotin (BV), a CD30-targeted antibody-drug conjugate used to treat cutaneous T-cell
  lymphoma (CTCL). However, clinical and histopathologic characterization of BV-associated
  rash (BVAR) is limited. Distinguishing BVAR from a patient's underlying CTCL can
  be challenging and can lead to treatment interruptions or even premature drug discontinuation.
  We performed a thorough clinical and histopathologic ...
disable_comments: true
---
Rash is one of the commonly observed adverse events with brentuximab vedotin (BV), a CD30-targeted antibody-drug conjugate used to treat cutaneous T-cell lymphoma (CTCL). However, clinical and histopathologic characterization of BV-associated rash (BVAR) is limited. Distinguishing BVAR from a patient's underlying CTCL can be challenging and can lead to treatment interruptions or even premature drug discontinuation. We performed a thorough clinical and histopathologic ...